Breast Cancer (advanced & metastatic) - bevacizumab (terminated appraisal) Technology appraisal TA 147 (25th June 2008)
NICE is unable to recommend the use in the NHS of bevacizumab in combination with paclitaxel for the first-line treatment of metastatic breast cancer because no evidence submission was received from the manufacturer or sponsor of the technology.
Click here for Technology Appraisal
Colorectal Cancer (metastatic) - cetuximab (terminated appraisal) Technology appraisal TA150 (25th June 2008)
NICE is unable to recommend the use in the NHS of cetuximab for the treatment of colorectal cancer following failure of oxaliplatin-containing chemotherapy because no evidence submission was received from the manufacturer or sponsor of the technology.
Click here for Technology Appraisal
Glioma (recurrent) - carmustine implants (terminated appraisal) Technology appraisal TA149 (25th June 2008)
NICE is unable to recommend the use in the NHS of carmustine implantsas an adjunct to surgery in patients with recurrent glioblastoma multiforme for whom surgical resection is indicated because no evidence submission was received from the manufacturer or sponsor of the technology.
Click here for Technology Appraisal
Head and neck cancer - cetuximab Technology appraisal TA145 (25th June 2008)
Cetuximab in combination with radiotherapy is recommended as a possible treatment for people with locally advanced squamous cell cancer of the head and neck if: they have a Karnofsky performance-status score of 90% or more, and all forms of platinum-based chemotherapy are considered inappropriate.
Click here for Guidance
Click here for Quick Reference Guide
Click here for Understanding NICE Guidance
Click here for Costing Template
Click here for Audit Support
Implantation of multifocal (non-accommodative) intraocular lenses during cataract surgery Interventional Procedure Guidance IPG 264 (25th June 2008)
A cataract is an eye condition in which the lens becomes cloudy over time. If untreated, cataracts can lead to blindness. During cataract surgery, the clouded lens is removed and replaced with an artificial lens, which provides clearer vision. Unlike standard intraocular lenses, a multifocal intraocular lens has areas with different focusing power with the aim of allowing near and distant objects to be seen without the need for spectacles.
Click here for Guidance
Click here for Understanding NICE Guidance
Click here for Consultation Comments
Lumbar infusion test for the investigation of normal pressure hydrocephalus Interventional Procedure Guidance IPG263 (25th June 2008)
Normal pressure hydrocephalus (NPH) is a condition in which a clear, colourless fluid called cerebrospinal fluid (or CSF) accumulates around the brain and spinal cord. Symptoms include abnormal gait, urinary incontinence and impaired cognitive function. NPH can be managed by surgical intervention, for example with shunt surgery. The lumbar infusion test may be useful for selecting those patients who are most likely to benefit from this type of surgery. This test involves the insertion of a lumbar needle through the skin of the lower back into the spinal sac, recording the pressure of the CSF as fluid is infused into the spinal sac.
Click here for Guidance
Click here for Understanding NICE Guidance
Lung cancer (non-small-cell) - bevacizumab (terminated appraisal) Technology appraisal TA148 (25th June 2008)
NICE is unable to recommend the use in the NHS of bevacizumab in addition to platinum-based chemotherapy for the first-line treatment of patients with unresectable advanced, metastatic or recurrent non-small-cell lung cancer (other than predominantly squamous cell histology) because no evidence submission was received from the manufacturer or sponsor of the technology.
Click here for Technology Appraisal
Obesity - rimonabant Technology appraisal TA144 (25th June 2008)
Rimonabant is recommended as a possible treatment for adults who are obese (that is, who have a BMI of 30 or more) or who are overweight (BMI of 27 or more) and have risk factors, such as type 2 diabetes or high levels of cholesterol. Rimonabant should be used at the same time as a calorie-controlled diet and exercise in people who have tried the weight-loss medicines orlistat and sibutramine, but they haven't worked or cannot be taken because side effects have occurred or are expected.
Click here for Guidance
Click here for Quick Reference Guide
Click here for Understanding NICE Guidance
Click here for Audit Support
Click here for Cost Template
Psoriasis - adalimumab Technology appraisal TA146 (25th June 2008)
Adalimumab is recommended as a possible treatment for adults with plaque psoriasis only if: their condition is severe and their condition has not improved with other treatments such as ciclosporin, methotrexate and PUVA (psoralen and long-wave ultraviolet radiation), or they have had side effects with these in the past or there is a medical reason why they should not be given these treatments.
Click here for NICE Guidance
Click here for Quick Reference Guide
Click here for Understanding NICE Guidance
Click here for Cost Template
Click here for Audit Support
Stent insertion for bleeding oesophageal varices Interventional Procedure Guidance IPG265 (25th June 2008)
Bleeding can occur from swollen veins in the gullet (oesophagus), which is potentially life threatening. This procedure involves temporarily insertion of a tube shape mesh covered in plastic (called a stent) into the oesophagus. The stent is expanded to the width of the gullet so that it presses against the varicose veins with the aim of stopping the bleeding. The stent is removed within 2 weeks.
Click here for Guidance
Click here for Understanding NICE Guidance
Click here for Consultation Comments
Surgical repair of vaginal wall prolapse using mesh Interventional Procedure Guidance IPG267 (25th June 2008)
Pelvic organ prolapse (POP) is a protrusion of one or more pelvic organs (bladder, rectum, uterus, vaginal vault, bowel) through vaginal fascia into the vagina and the downward displacement ('prolapse') of the associated vaginal wall from its normal location to or outside the vaginal opening. POP affects a woman's quality of life by its local physical effects (pressure, bulging, heaviness or discomfort) or its effect on urinary, bowel or sexual function. POP can be classified according to the compartment affected as: anterior vaginal wall prolapse (urethrocele, cystocele); posterior vaginal wall prolapse (rectocele, enterocele); prolapse of the cervix or uterus; and prolapse of the vaginal vault (which can only occur after prior hysterectomy). A woman can present with prolapse of one or more of these sites.
Click here for Guidance
Click here for Understanding NICE Guidance
Click here for Audit Support
Click here for the Consultation Comments
Transcatheter aortic valve implantation for aortic stenosis Interventional Procedure Guidance IPG266 (25th June 2008)
Aortic stenosis occurs when the aortic valve, which separates the main pumping chamber of the heart from the main circulation, becomes partially blocked. This reduces the flow of blood out of the heart. Transcatheter aortic valve implantation is an alternative to surgical valve replacement. The procedure is performed through a tube, which is inserted into either a blood vessel at the top of the leg (transluminal approach) or into the apex of the heart (transapical approach). Through this tube, a replacement valve is positioned and deployed over the faulty valve.
Click here for Guidance
Click here for Understanding NICE Guidance
Click here for the Consultation Comments
Interventional procedures programme process guide consultation (18th June 2008)
NICE is undertaking a review of the processes used in its Interventional Procedures Programme, which issues guidance on the safety and efficacy of interventional procedures being used in the NHS for the first time. NICE is now consulting on the updated Interventional Procedures Process Guide for a period of 12 weeks. Closing date for comments is 10th September 2008.
Click here for the Cover letter
Click here for the Consultation
Needle and syringe programmes: consultation on the evidence (20th June 2008)
NICE was asked by the Department of Health (DH) to develop public health intervention guidance to encourage the optimal provision of needle exchange schemes amongst injecting drug misusers. The scope is available from the NICE website. Closing date for comments is 18th July 2008.
Click here for the Consultation
Hepatitis B - telbivudine: final appraisal determination (24th June 2008)
After considering the feedback from consultation, the Appraisal Committee has prepared a Final Appraisal Determination (FAD) on Telbivudine for the treatment of chronic hepatitis B and submitted it to the Institute. The FAD has been sent to the formal consultees for this appraisal who have 15 working days to consider whether they wish to appeal against it. Subject to any appeal by consultees, the FAD may be used as the basis for the Institute's guidance on the use of the appraised technology in the NHS in England and Wales. Closing date for comments is 8th July 2008.
Click here for the FAD
Hepatitis B - entecavir: final appraisal determination (24th June 2008)
After considering the feedback from consultation, the Appraisal Committee has prepared a Final Appraisal Determination (FAD) on Entecavir for the treatment of chronic hepatitis B and submitted it to the Institute. The FAD has been sent to the formal consultees for this appraisal who have 15 working days to consider whether they wish to appeal against it. Subject to any appeal by consultees, the FAD may be used as the basis for the Institute's guidance on the use of the appraised technology in the NHS in England and Wales. Closing date for comments is 8th July 2008.
Click here for the FAD
Looked after children: consultation on the draft scope (25th June 2008)
NICE & SCIE were asked by the Department of Health to develop guidance on looked after children. Closing date for comments is 23rd July 2008.
Click here for the Draft scope
Click here for the Comments form
Prevention of skin cancer: consultation on the draft scope (27th June 2008)
NICE was asked by the Department of Health to develop guidance on the prevention of skin cancer. Closing date for comments is 25th July 2008.
Click here for the Draft scope
Click here for the Comments form
Functional electrical stimulation for drop foot of central neurological origin (interventional procedures consultation) (30th June 2008)
Drop foot is the inability to lift the foot and toes when walking. It can result from conditions such as stroke, multiple sclerosis or spinal cord injury. Functional electrical stimulation involves stimulation of the peripheral nerves that supply the paralysed muscle using electrodes that may be implanted or placed on the surface of the skin. The aim is to restore muscular function. Closing date for comments is 28th July 2008.
Click here for the Consultation
Electrically-stimulated intravesical chemotherapy for superficial bladder cancer (interventional procedures consultation) (30th June 2008)
This procedure, also known as electromotive drug administration (EMDA) of intravesical chemotherapy, can be used for patients with bladder cancer, either before or after surgery. A solution including a chemotherapy drug is injected into the bladder using a thin tube inserted through the urethra. At the same time, an electrode is inserted in the bladder and other electrodes are placed on the skin of the lower abdomen. An electric current is then created with the aim of improving absorption of the chemotherapeutic drugs.
Click here for the Consultation
NICE is unable to recommend the use in the NHS of bevacizumab in combination with paclitaxel for the first-line treatment of metastatic breast cancer because no evidence submission was received from the manufacturer or sponsor of the technology.
Click here for Technology Appraisal
Colorectal Cancer (metastatic) - cetuximab (terminated appraisal) Technology appraisal TA150 (25th June 2008)
NICE is unable to recommend the use in the NHS of cetuximab for the treatment of colorectal cancer following failure of oxaliplatin-containing chemotherapy because no evidence submission was received from the manufacturer or sponsor of the technology.
Click here for Technology Appraisal
Glioma (recurrent) - carmustine implants (terminated appraisal) Technology appraisal TA149 (25th June 2008)
NICE is unable to recommend the use in the NHS of carmustine implantsas an adjunct to surgery in patients with recurrent glioblastoma multiforme for whom surgical resection is indicated because no evidence submission was received from the manufacturer or sponsor of the technology.
Click here for Technology Appraisal
Head and neck cancer - cetuximab Technology appraisal TA145 (25th June 2008)
Cetuximab in combination with radiotherapy is recommended as a possible treatment for people with locally advanced squamous cell cancer of the head and neck if: they have a Karnofsky performance-status score of 90% or more, and all forms of platinum-based chemotherapy are considered inappropriate.
Click here for Guidance
Click here for Quick Reference Guide
Click here for Understanding NICE Guidance
Click here for Costing Template
Click here for Audit Support
Implantation of multifocal (non-accommodative) intraocular lenses during cataract surgery Interventional Procedure Guidance IPG 264 (25th June 2008)
A cataract is an eye condition in which the lens becomes cloudy over time. If untreated, cataracts can lead to blindness. During cataract surgery, the clouded lens is removed and replaced with an artificial lens, which provides clearer vision. Unlike standard intraocular lenses, a multifocal intraocular lens has areas with different focusing power with the aim of allowing near and distant objects to be seen without the need for spectacles.
Click here for Guidance
Click here for Understanding NICE Guidance
Click here for Consultation Comments
Lumbar infusion test for the investigation of normal pressure hydrocephalus Interventional Procedure Guidance IPG263 (25th June 2008)
Normal pressure hydrocephalus (NPH) is a condition in which a clear, colourless fluid called cerebrospinal fluid (or CSF) accumulates around the brain and spinal cord. Symptoms include abnormal gait, urinary incontinence and impaired cognitive function. NPH can be managed by surgical intervention, for example with shunt surgery. The lumbar infusion test may be useful for selecting those patients who are most likely to benefit from this type of surgery. This test involves the insertion of a lumbar needle through the skin of the lower back into the spinal sac, recording the pressure of the CSF as fluid is infused into the spinal sac.
Click here for Guidance
Click here for Understanding NICE Guidance
Lung cancer (non-small-cell) - bevacizumab (terminated appraisal) Technology appraisal TA148 (25th June 2008)
NICE is unable to recommend the use in the NHS of bevacizumab in addition to platinum-based chemotherapy for the first-line treatment of patients with unresectable advanced, metastatic or recurrent non-small-cell lung cancer (other than predominantly squamous cell histology) because no evidence submission was received from the manufacturer or sponsor of the technology.
Click here for Technology Appraisal
Obesity - rimonabant Technology appraisal TA144 (25th June 2008)
Rimonabant is recommended as a possible treatment for adults who are obese (that is, who have a BMI of 30 or more) or who are overweight (BMI of 27 or more) and have risk factors, such as type 2 diabetes or high levels of cholesterol. Rimonabant should be used at the same time as a calorie-controlled diet and exercise in people who have tried the weight-loss medicines orlistat and sibutramine, but they haven't worked or cannot be taken because side effects have occurred or are expected.
Click here for Guidance
Click here for Quick Reference Guide
Click here for Understanding NICE Guidance
Click here for Audit Support
Click here for Cost Template
Psoriasis - adalimumab Technology appraisal TA146 (25th June 2008)
Adalimumab is recommended as a possible treatment for adults with plaque psoriasis only if: their condition is severe and their condition has not improved with other treatments such as ciclosporin, methotrexate and PUVA (psoralen and long-wave ultraviolet radiation), or they have had side effects with these in the past or there is a medical reason why they should not be given these treatments.
Click here for NICE Guidance
Click here for Quick Reference Guide
Click here for Understanding NICE Guidance
Click here for Cost Template
Click here for Audit Support
Stent insertion for bleeding oesophageal varices Interventional Procedure Guidance IPG265 (25th June 2008)
Bleeding can occur from swollen veins in the gullet (oesophagus), which is potentially life threatening. This procedure involves temporarily insertion of a tube shape mesh covered in plastic (called a stent) into the oesophagus. The stent is expanded to the width of the gullet so that it presses against the varicose veins with the aim of stopping the bleeding. The stent is removed within 2 weeks.
Click here for Guidance
Click here for Understanding NICE Guidance
Click here for Consultation Comments
Surgical repair of vaginal wall prolapse using mesh Interventional Procedure Guidance IPG267 (25th June 2008)
Pelvic organ prolapse (POP) is a protrusion of one or more pelvic organs (bladder, rectum, uterus, vaginal vault, bowel) through vaginal fascia into the vagina and the downward displacement ('prolapse') of the associated vaginal wall from its normal location to or outside the vaginal opening. POP affects a woman's quality of life by its local physical effects (pressure, bulging, heaviness or discomfort) or its effect on urinary, bowel or sexual function. POP can be classified according to the compartment affected as: anterior vaginal wall prolapse (urethrocele, cystocele); posterior vaginal wall prolapse (rectocele, enterocele); prolapse of the cervix or uterus; and prolapse of the vaginal vault (which can only occur after prior hysterectomy). A woman can present with prolapse of one or more of these sites.
Click here for Guidance
Click here for Understanding NICE Guidance
Click here for Audit Support
Click here for the Consultation Comments
Transcatheter aortic valve implantation for aortic stenosis Interventional Procedure Guidance IPG266 (25th June 2008)
Aortic stenosis occurs when the aortic valve, which separates the main pumping chamber of the heart from the main circulation, becomes partially blocked. This reduces the flow of blood out of the heart. Transcatheter aortic valve implantation is an alternative to surgical valve replacement. The procedure is performed through a tube, which is inserted into either a blood vessel at the top of the leg (transluminal approach) or into the apex of the heart (transapical approach). Through this tube, a replacement valve is positioned and deployed over the faulty valve.
Click here for Guidance
Click here for Understanding NICE Guidance
Click here for the Consultation Comments
Interventional procedures programme process guide consultation (18th June 2008)
NICE is undertaking a review of the processes used in its Interventional Procedures Programme, which issues guidance on the safety and efficacy of interventional procedures being used in the NHS for the first time. NICE is now consulting on the updated Interventional Procedures Process Guide for a period of 12 weeks. Closing date for comments is 10th September 2008.
Click here for the Cover letter
Click here for the Consultation
Needle and syringe programmes: consultation on the evidence (20th June 2008)
NICE was asked by the Department of Health (DH) to develop public health intervention guidance to encourage the optimal provision of needle exchange schemes amongst injecting drug misusers. The scope is available from the NICE website. Closing date for comments is 18th July 2008.
Click here for the Consultation
Hepatitis B - telbivudine: final appraisal determination (24th June 2008)
After considering the feedback from consultation, the Appraisal Committee has prepared a Final Appraisal Determination (FAD) on Telbivudine for the treatment of chronic hepatitis B and submitted it to the Institute. The FAD has been sent to the formal consultees for this appraisal who have 15 working days to consider whether they wish to appeal against it. Subject to any appeal by consultees, the FAD may be used as the basis for the Institute's guidance on the use of the appraised technology in the NHS in England and Wales. Closing date for comments is 8th July 2008.
Click here for the FAD
Hepatitis B - entecavir: final appraisal determination (24th June 2008)
After considering the feedback from consultation, the Appraisal Committee has prepared a Final Appraisal Determination (FAD) on Entecavir for the treatment of chronic hepatitis B and submitted it to the Institute. The FAD has been sent to the formal consultees for this appraisal who have 15 working days to consider whether they wish to appeal against it. Subject to any appeal by consultees, the FAD may be used as the basis for the Institute's guidance on the use of the appraised technology in the NHS in England and Wales. Closing date for comments is 8th July 2008.
Click here for the FAD
Looked after children: consultation on the draft scope (25th June 2008)
NICE & SCIE were asked by the Department of Health to develop guidance on looked after children. Closing date for comments is 23rd July 2008.
Click here for the Draft scope
Click here for the Comments form
Prevention of skin cancer: consultation on the draft scope (27th June 2008)
NICE was asked by the Department of Health to develop guidance on the prevention of skin cancer. Closing date for comments is 25th July 2008.
Click here for the Draft scope
Click here for the Comments form
Functional electrical stimulation for drop foot of central neurological origin (interventional procedures consultation) (30th June 2008)
Drop foot is the inability to lift the foot and toes when walking. It can result from conditions such as stroke, multiple sclerosis or spinal cord injury. Functional electrical stimulation involves stimulation of the peripheral nerves that supply the paralysed muscle using electrodes that may be implanted or placed on the surface of the skin. The aim is to restore muscular function. Closing date for comments is 28th July 2008.
Click here for the Consultation
Electrically-stimulated intravesical chemotherapy for superficial bladder cancer (interventional procedures consultation) (30th June 2008)
This procedure, also known as electromotive drug administration (EMDA) of intravesical chemotherapy, can be used for patients with bladder cancer, either before or after surgery. A solution including a chemotherapy drug is injected into the bladder using a thin tube inserted through the urethra. At the same time, an electrode is inserted in the bladder and other electrodes are placed on the skin of the lower abdomen. An electric current is then created with the aim of improving absorption of the chemotherapeutic drugs.
Click here for the Consultation
No comments:
Post a Comment